Local paclitaxel delivery in peripheral vascular disease [1]

New England Journal of Medicine

Volumn 358, Issue 22, 2008, Pages 2406-2407

  Schillinger, Martin ^a   Minar, Erich ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

COMPARATIVE STUDY; CONTROL GROUP; FOLLOW UP; HUMAN; LETTER; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; SUPERFICIAL FEMORAL ARTERY; TREATMENT DURATION; ARTERY DISEASE; DISEASE SEVERITY; LEG REVASCULARIZATION; SYMPTOMATOLOGY; FEMORAL ARTERY; NOTE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPLITEAL ARTERY; RECURRENT DISEASE; VASCULAR PATENCY;

ANGIOPLASTY, BALLOON; ARTERIAL OCCLUSIVE DISEASES; FEMORAL ARTERY; HUMANS; PACLITAXEL; POPLITEAL ARTERY; RECURRENCE; VASCULAR PATENCY;

EID: 44349160802     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc080576     Document Type: Letter

References (4)

1. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008;358:689-99.
2. Diehm N, Baumgartner I, Jaff M, et al. A call for uniform reporting standards in studies assessing endovascular treatment for chronic ischaemia of lower limb arteries. Eur Heart J 2007;28:798-805.
3. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006;354:1879-88.
4. Schillinger M, Sabeti S, Dick P, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation 2007;115:2745-9.